Buy or sell ViaCyte stock pre IPO via an EquityZen fund
Preclinical Therapeutic Company
About ViaCyte Stock
ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Senior Vice President, Science & Technology
Vice President, Business Development and Strategy
Steven R. Altman
President and Chief Executive Officer